Jiangsu CoWin Biotech Co., Ltd. (SHA:688426)
18.18
-0.81 (-4.27%)
At close: Jun 2, 2026
Jiangsu CoWin Biotech Revenue
Jiangsu CoWin Biotech had revenue of 59.00M CNY in the quarter ending March 31, 2026, with 37.19% growth. This brings the company's revenue in the last twelve months to 209.51M, up 49.57% year-over-year. In the year 2025, Jiangsu CoWin Biotech had annual revenue of 193.52M with 53.74% growth.
Revenue (ttm)
209.51M
Revenue Growth
+49.57%
P/S Ratio
9.54
Revenue / Employee
272.45K
Employees
769
Market Cap
2.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 193.52M | 67.64M | 53.74% |
| Dec 31, 2024 | 125.88M | -45.47M | -26.54% |
| Dec 31, 2023 | 171.34M | -350.26M | -67.15% |
| Dec 31, 2022 | 521.60M | 183.14M | 54.11% |
| Dec 31, 2021 | 338.46M | 105.25M | 45.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Universal Biotech | 1.13B |
| Zhejiang East Asia Pharmaceutical | 1.01B |
| Shandong Sito Bio-technology | 954.76M |
| Guiyang Xintian Pharmaceutical | 735.18M |
| Jilin Jian Yisheng Pharmaceutical | 659.66M |
| Tiansheng Pharmaceutical Group | 514.09M |
| Shanghai Model Organisms Center | 432.55M |
| Cabio Biotech (Wuhan) | 418.18M |